135 related articles for article (PubMed ID: 12604504)
41. Insulin-like growth factor binding proteins modulate Müller cell responses to insulin-like growth factors.
King JL; Guidry C
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2848-55. PubMed ID: 15277512
[TBL] [Abstract][Full Text] [Related]
42. Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25).
López-Bermejo A; Khosravi J; Fernández-Real JM; Hwa V; Pratt KL; Casamitjana R; Garcia-Gil MM; Rosenfeld RG; Ricart W
Diabetes; 2006 Aug; 55(8):2333-9. PubMed ID: 16873698
[TBL] [Abstract][Full Text] [Related]
43. Insulin-like growth factor I in cats: validation of an enzyme-linked immunosorbent assay and determination of biologic variation.
Strage EM; Theodorsson E; Ström Holst B; Lilliehöök I; Lewitt MS
Vet Clin Pathol; 2015 Dec; 44(4):542-51. PubMed ID: 26418310
[TBL] [Abstract][Full Text] [Related]
44. The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease.
Janssen JAMJL; Varewijck AJ; Brugts MP
Growth Horm IGF Res; 2019; 48-49():16-28. PubMed ID: 31493625
[TBL] [Abstract][Full Text] [Related]
45. Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling.
Varewijck AJ; Brugts MP; Frystyk J; Goudzwaard JA; Uitterlinden P; Waaijers AM; Feng Y; Dimitrov DS; Lamberts SW; Hofland LJ; Janssen JA
Mol Cell Endocrinol; 2013 Jan; 365(1):17-24. PubMed ID: 22982059
[TBL] [Abstract][Full Text] [Related]
46. Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome.
Brugts MP; van Duijn CM; Hofland LJ; Witteman JC; Lamberts SW; Janssen JA
Diabetes; 2010 Feb; 59(2):505-8. PubMed ID: 20103714
[TBL] [Abstract][Full Text] [Related]
47. Cell-based assays for IGF-I bioactivity measurement: overview, limitations and current trends.
Ramadhin C; Pillay B; Olaniran AO
Growth Factors; 2014 Jun; 32(3-4):130-8. PubMed ID: 25060037
[TBL] [Abstract][Full Text] [Related]
48. Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring.
Vitale G; Brugts MP; Ogliari G; Castaldi D; Fatti LM; Varewijck AJ; Lamberts SW; Monti D; Bucci L; Cevenini E; Cavagnini F; Franceschi C; Hofland LJ; Mari D; Janssen J
Aging (Albany NY); 2012 Sep; 4(9):580-9. PubMed ID: 22983440
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients.
Chestnut RE; Quarmby V
J Immunol Methods; 2002 Jan; 259(1-2):11-24. PubMed ID: 11730837
[TBL] [Abstract][Full Text] [Related]
50. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay.
Costello M; Baxter RC; Scott CD
J Clin Endocrinol Metab; 1999 Feb; 84(2):611-7. PubMed ID: 10022425
[TBL] [Abstract][Full Text] [Related]
51. Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays.
Sadick MD; Intintoli A; Quarmby V; McCoy A; Canova-Davis E; Ling V
J Pharm Biomed Anal; 1999 May; 19(6):883-91. PubMed ID: 10698554
[TBL] [Abstract][Full Text] [Related]
52. Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity.
Janssen JA; van der Lely AJ; Lamberts SW
J Endocrinol Invest; 2003 Jun; 26(6):588-94. PubMed ID: 12952376
[TBL] [Abstract][Full Text] [Related]
53. Multicentre collaborative study to calibrate IGF-II by bioassay and immunoassay: establishment of the First WHO Reference Reagent.
Rafferty B; Rigsby P; Gaines-Das RE
Growth Horm IGF Res; 2001 Feb; 11(1):18-23. PubMed ID: 11437470
[TBL] [Abstract][Full Text] [Related]
54. Quantitative measurement of IGF-I and its use in diagnosing and monitoring treatment of disorders of growth hormone secretion.
Clemmons DR
Endocr Dev; 2005; 9():55-65. PubMed ID: 15879688
[TBL] [Abstract][Full Text] [Related]
55. Utility of free IGF-I measurements.
Frystyk J
Pituitary; 2007; 10(2):181-7. PubMed ID: 17429595
[TBL] [Abstract][Full Text] [Related]
56. Determination of insulin-like growth factor 1 in dogs using a commercially available immunoradiometric assay1).
Jensen AL; Høier R
Eur J Clin Chem Clin Biochem; 1995 Dec; 33(12):939-945. PubMed ID: 8845426
[TBL] [Abstract][Full Text] [Related]
57. The current status of IGF-I assays--a 2009 update.
Frystyk J; Freda P; Clemmons DR
Growth Horm IGF Res; 2010 Feb; 20(1):8-18. PubMed ID: 19818658
[TBL] [Abstract][Full Text] [Related]
58. Current reliability of the Immulite® assay for measurement of serum IGF-1 in the Brazilian adult population.
Rosario PW; Gadelha MR
Arch Endocrinol Metab; 2015 Apr; 59(2):195-6. PubMed ID: 25993685
[No Abstract] [Full Text] [Related]
59. How should insulin-like growth factor I be measured? A consensus statement.
Ranke MB; Feldt-Rasmussen U; Bang P; Baxter RC; Camacho-Hübner C; Clemmons DR; Juul A; Orskov H; Strasburger CJ
Horm Res; 2001; 55 Suppl 2():106-9. PubMed ID: 11684887
[No Abstract] [Full Text] [Related]
60. Bioactivity Determination of a Therapeutic Recombinant Human Keratinocyte Growth Factor by a Validated Cell-based Bioassay.
Yao W; Guo Y; Qin X; Yu L; Shi X; Liu L; Zhou Y; Hu J; Rao C; Wang J
Molecules; 2019 Feb; 24(4):. PubMed ID: 30769959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
